Literature DB >> 28863860

Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models.

Michaeline Hebron1, Margo Peyton1, Xiaoguang Liu1, Xiaokong Gao1, Ruochong Wang1, Irina Lonskaya1, Charbel E-H Moussa2.   

Abstract

The role of cell surface tyrosine kinase collagen-activated receptors known as discoidin domain receptors (DDRs) is unknown in neurodegenerative diseases. We detect up-regulation in DDRs level in post-mortem Alzheimer and Parkinson brains. Lentiviral shRNA knockdown of DDR1 and DDR2 reduces the levels of α-synuclein, tau, and β-amyloid and prevents cell loss in vivo and in vitro. DDR1 and DDR2 knockdown alters brain immunity and significantly reduces the level of triggering receptor expressed on myeloid cells (TREM)-2 and microglia. These studies suggest that DDR1 and DDR2 inhibition is a potential target to clear neurotoxic proteins and reduce inflammation in neurodegeneration.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer; DDRs; Microglia; Parkinson; TREM2

Mesh:

Substances:

Year:  2017        PMID: 28863860     DOI: 10.1016/j.jneuroim.2017.07.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.

Authors:  Fernando L Pagan; Michaeline L Hebron; Barbara Wilmarth; Yasar Torres-Yaghi; Abigail Lawler; Elizabeth E Mundel; Nadia Yusuf; Nathan J Starr; Joy Arellano; Helen H Howard; Margo Peyton; Sara Matar; Xiaoguang Liu; Alan J Fowler; Sorell L Schwartz; Jaeil Ahn; Charbel Moussa
Journal:  Pharmacol Res Perspect       Date:  2019-03-12

2.  Data-Driven Analysis of Age, Sex, and Tissue Effects on Gene Expression Variability in Alzheimer's Disease.

Authors:  Lavida R K Brooks; George I Mias
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

3.  CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease.

Authors:  Alan J Fowler; Jaeil Ahn; Michaeline Hebron; Timothy Chiu; Reem Ayoub; Sanjana Mulki; Habtom Ressom; Yasar Torres-Yaghi; Barbara Wilmarth; Fernando L Pagan; Charbel Moussa
Journal:  Neurol Genet       Date:  2021-11-12

4.  Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling.

Authors:  Jieun Kim; Hyun-Ju Lee; Jin-Hee Park; Byung-Yoon Cha; Hyang-Sook Hoe
Journal:  J Neuroinflammation       Date:  2022-07-15       Impact factor: 9.587

5.  Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.

Authors:  Alan J Fowler; Michaeline Hebron; Kaluvu Balaraman; Wangke Shi; Alexander A Missner; Jonathan D Greenzaid; Timothy L Chiu; Clementina Ullman; Ethan Weatherdon; Val Duka; Yasar Torres-Yaghi; Fernando L Pagan; Xiaoguang Liu; Habtom Ressom; Jaeil Ahn; Christian Wolf; Charbel Moussa
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

6.  Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.

Authors:  Sapana Bansod; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

7.  BAP31 regulates IRAK1-dependent neuroinflammation in microglia.

Authors:  Xia Liu; Kun Jiao; Cong-Cong Jia; Guo-Xun Li; Qing Yuan; Ji-Kai Xu; Yue Hou; Bing Wang
Journal:  J Neuroinflammation       Date:  2019-12-28       Impact factor: 8.322

8.  Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.

Authors:  Raymond S Turner; Michaeline L Hebron; Abigail Lawler; Elizabeth E Mundel; Nadia Yusuf; J Nathan Starr; Muhammad Anjum; Fernando Pagan; Yasar Torres-Yaghi; Wangke Shi; Sanjana Mulki; Dalila Ferrante; Sara Matar; Xiaoguang Liu; Giuseppe Esposito; Frank Berkowitz; Xiong Jiang; Jaeil Ahn; Charbel Moussa
Journal:  Ann Neurol       Date:  2020-05-28       Impact factor: 10.422

9.  Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.

Authors:  Fernando L Pagan; Barbara Wilmarth; Yasar Torres-Yaghi; Michaeline L Hebron; Sanjana Mulki; Dalila Ferrante; Sara Matar; Jaeil Ahn; Charbel Moussa
Journal:  Mov Disord       Date:  2020-11-20       Impact factor: 10.338

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.